<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Complement-mediated hemolytic uremic syndrome in children</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Complement-mediated hemolytic uremic syndrome in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Complement-mediated hemolytic uremic syndrome in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Niaudet, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Olivia Gillion Boyer, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tej K Mattoo, MD, DCH, FRCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 03, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hemolytic uremic syndrome (HUS) is defined by the simultaneous occurrence of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury [<a href="#rid1">1</a>]. The most common cause of HUS is due to Shiga toxin-producing <em>Escherichia coli</em> (STEC). Research over the last 20 years has shown that complement dysregulation accounts for most of the non-STEC cases of HUS. This discovery has had a major impact on identifying the underlying cause of familial HUS, and on the management of these patients, who historically have had a poor prognosis.</p><p>The clinical manifestation, diagnosis, and management of complement-mediated HUS will be reviewed here. An overview of HUS and topics on the clinical manifestations, diagnosis, and management of STEC-HUS in children are found separately. (See  <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">"Overview of hemolytic uremic syndrome in children"</a> and  <a class="medical medical_review" href="/z/d/html/6081.html" rel="external">"Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children"</a> and  <a class="medical medical_review" href="/z/d/html/6097.html" rel="external">"Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children"</a>.)</p><p>Complement-mediated thrombotic microangiopathy is also discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/114693.html" rel="external">"Thrombotic microangiopathies (TMAs) with acute kidney injury (AKI) in adults: CM-TMA and ST-HUS", section on 'Causes of CM-TMA'</a>.)</p><p class="headingAnchor" id="H1257181106"><span class="h1">DEFINITIONS</span></p><p>Thrombotic microangiopathy describes a specific pathologic lesion in which abnormalities in the vessel wall of arterioles and capillaries lead to microvascular thrombosis. It includes several primary disorders including thrombotic thrombocytopenic purpura, Shiga toxin-mediated HUS and complement-mediated HUS or TMA. (See  <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"</a>.) </p><p class="headingAnchor" id="H2139453078"><span class="h2">Classification</span><span class="headingEndMark"> — </span>In the past, HUS had been divided into diarrhea-positive and diarrhea-negative HUS. The former, also referred to as typical HUS, primarily resulted from Shiga toxin-producing Escherichia coli (STEC) infections, and less frequently from Shigella dysenteriae type 1 infection. All other causes of HUS were referred to as atypical HUS or assigned to the diarrhea-negative HUS, even though some patients with non-STEC-associated HUS also presented with diarrhea.</p><p>However, ongoing research has provided a better understanding of the underlying causes of HUS, especially those due to genetic mutations in the alternative pathway of complement [<a href="#rid2">2,3</a>]. As a result, the following classification has been developed based on pathophysiological considerations and triggering factors [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hereditary causes of TMA/HUS [<a href="#rid5">5</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complement gene mutations (see <a class="local">'Genetic variants'</a> below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inborn errors of cobalamin C metabolism</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diacylglycerol kinase epsilon (DGKE) gene mutations (see  <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">"Overview of hemolytic uremic syndrome in children", section on 'Coagulation pathway'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acquired causes of HUS:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infection:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Shiga toxin-producing Escherichia coli (STEC) (see  <a class="medical medical_review" href="/z/d/html/6081.html" rel="external">"Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children"</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Streptococcus pneumoniae (see  <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">"Overview of hemolytic uremic syndrome in children", section on 'Streptococcus pneumoniae'</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Human immunodeficiency viral infection</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Autoantibodies to complement factors:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Drug toxicity, particularly in patients with cancer or solid organ transplant recipients</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Rare occurrences in pregnant patients or those with autoimmune disorders (eg, systemic lupus erythematosus)</p><p></p><p class="headingAnchor" id="H1369647994"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Complement-mediated HUS is a relatively rare disorder with an estimated prevalence of seven per one million children in Europe [<a href="#rid6">6</a>]. Most complement-mediated HUS cases are due to gene mutations of complement factors [<a href="#rid7">7-9</a>]. Antibodies to complement proteins have been implicated in the etiology of 6 to 10 percent of patients with complement-mediated HUS [<a href="#rid10">10</a>]. In addition, patients may have concurrent genetic mutations and antibodies to complement proteins [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H104164148"><span class="h2">Genetic complement disorders</span><span class="headingEndMark"> — </span>Variants in the following identified genes that encode complement proteins appear to account for at least 50 to 60 percent of non-Shiga toxin-producing <em>E. coli</em> (STEC) HUS cases [<a href="#rid7">7,8,12-15</a>]. The reported relative frequency of each affected gene for non-STEC-HUS cases is also listed:</p><p class="bulletIndent1"><span class="glyph">●</span>Complement factor H (<em>CFH</em>, 20 to 30 percent)</p><p class="bulletIndent1"><span class="glyph">●</span><em>CD46</em>, previously known as membrane cofactor protein (5 to 15 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Complement factor I (<em>CFI</em>, 4 to 10 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Complement factor 3 (<em>C3</em>, 2 to 10 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Complement factor B (<em>CFB</em>, 1 to 4 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombomodulin gene (<em>THBD, </em>3 to 5 percent)</p><p></p><p>It is likely that the percent of noninfectious HUS cases due to a complement disorder will rise with ongoing research identifying new gene variants. As an example, a genetic analysis of 400 patients with atypical HUS (aHUS) identified <em>VTN, </em>which encodes vitronectin, an inhibitor of the terminal complement pathway, as a novel gene associated with HUS [<a href="#rid15">15</a>]. </p><p>In addition, a significant number of patients with complement-mediated HUS have variants of more than one complement protein [<a href="#rid2">2,7,10,16</a>]. It is important to stress that the penetrance of the disease is low, as less than 20 percent of family members carrying the same variant as the patient with complement-mediated HUS will be affected with the disease [<a href="#rid17">17</a>]. The risk is higher in the siblings and the offspring of patients than in parents. Moreover, rare variants in the complement genes with minor allele frequencies (MAFs) of &lt;1 and &lt;0.1 percent are present in 12 and 3.7 percent of healthy individuals, respectively. Therefore, genetic counselling in aHUS requires the input of trained geneticists and experts who have a comprehensive view of complement biology [<a href="#rid18">18</a>]. (See <a class="local">'Factor H'</a> below.)</p><p class="headingAnchor" id="H29839687"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The complement proteins associated with complement-mediated HUS are components of the alternative complement pathway. HUS results from a loss-of-function variant in a regulatory gene (<em>CFH</em>, <em>CFI</em>, or <em>CD46</em>) or a gain-of-function variant in an effector gene (<em>CFB</em> or <em>C3</em>). The proposed mechanism for the development of HUS is a trigger event, such as infection or pregnancy, in a susceptible individual with a gene variant(s) or antibodies to complement proteins, which leads to uninhibited continuous activation of the alternative pathway resulting in the formation of the membrane attack complex (MAC) [<a href="#rid2">2,12,19</a>]. This causes renal endothelium damage leading to activation of the coagulations cascade and thrombotic microangiopathy. (See  <a class="medical medical_review" href="/z/d/html/3968.html" rel="external">"Complement pathways", section on 'Alternative pathway'</a>.)</p><p>Data from an animal study suggest that <em>C5</em> activation is important in the pathogenesis of HUS, thus supporting the use of <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a>, a humanized monoclonal antibody to <em>C5</em> [<a href="#rid20">20</a>]. (See <a class="local">'Complement blockade (eculizumab)'</a> below.)</p><p class="headingAnchor" id="H3778582098"><span class="h1">COMPLEMENT ANTIBODIES</span><span class="headingEndMark"> — </span>Complement factor H (CFH) antibodies of the IgG class have been reported in approximately 8 to 10 percent of patients with atypical HUS (ie, non-Shiga toxin-producing <em>E. coli</em> [STEC]-HUS) [<a href="#rid21">21-27</a>]. These antibodies detected by enzyme-linked immunosorbent assay (ELISA) interfere with the binding of CFH to the C3 convertase and are associated with a defective CFH-dependent cell protection [<a href="#rid28">28</a>]. Gastrointestinal symptoms (diarrhea and vomiting) are common as well as relapses, which typically occur within the first two years after initial presentation [<a href="#rid21">21,29</a>].</p><p>A study of 308 cases of atypical HUS (Newcastle cohort) reported the presence of CFH antibodies in 13 of 142 screened patients (9.2 percent) [<a href="#rid25">25</a>]. Most of these patients also had homozygous or compound heterozygous deletion of <em>CFHR1</em> and/or <em>CFHR3</em> and/or <em>CFHR4</em> genes, suggesting that this deletion has a pathogenetic role in the development of anti-CFH antibodies [<a href="#rid21">21,23,25,30,31</a>]. Variants in other complement genes (<em>CFH</em>, complement factors I and B, <em>CD46</em>, and <em>C3</em>) also were identified in a minority of patients [<a href="#rid25">25</a>]. These findings suggest that in some patients, multiple "hits" to the complement system may be necessary for the clinical presentation of complement-mediated HUS [<a href="#rid25">25,32</a>].</p><p>A study of 186 cases of atypical HUS reported the presence of autoantibodies to factor H of the IgM class in 7 cases (3.8 percent), with a higher frequency in patients with atypical HUS following bone marrow transplantation [<a href="#rid33">33</a>]. No association was observed between anti-factor H IgM and homozygous deletions involving CFHR3-CFHR1.</p><p class="headingAnchor" id="H179048059"><span class="h1">GENETIC VARIANTS</span></p><p class="headingAnchor" id="H9"><span class="h2">Factor H</span><span class="headingEndMark"> — </span>Variants of the complement factor H (<em>CFH</em>) gene, which encodes a regulatory protein in the alternative complement pathway, and CFH-related proteins (CFHR) are the most frequently identified genetic abnormalities seen in patients with complement-mediated HUS [<a href="#rid9">9,34</a>]. CFH in conjunction with complement factor I (CFI) competes with complement factor B (CFB) for C3b binding and accelerates C3 convertase decay. Over 100 variants of <em>CFH</em> have been reported, most of which are missense variants. Not all variants affect the levels of CFH and C3 [<a href="#rid35">35</a>]. In these patients, variants generally affect the C-terminal region, which is important for binding to C3b, glucosaminoglycans, heparin, and endothelial cells [<a href="#rid36">36,37</a>]. Other variants are located throughout the gene and are associated with low levels of CFH antigen. </p><p>The interpretation of sequence variants (which includes <em>CFH </em>variants) is challenging for clinicians as noted by a joint consensus recommendation of the American College of Medical Genetics (ACMG) and Genomics and the Association for Molecular Pathology [<a href="#rid38">38</a>]. In one report, 105 <em>CFH</em> missense variants were functionally characterized, of which 79 were novel [<a href="#rid35">35</a>]. Almost two-thirds of these novel variants were functionally indistinguishable from wild-type FH protein and therefore were classified as benign according to the ACMG criteria. Most of these benign variants are located in the N-terminal and midregions of FH, whereas most C-terminal variants are pathogenic. In this study, allele frequency was not a useful indicator of pathogenicity since 2.3 percent of the general population bear one rare <em>CFH</em> variant with an allele frequency &lt;0.1 percent. Carriers of pathogenic <em>CFH</em> variants were younger at diagnosis and had more severe aHUS with more frequent recurrences than carriers of benign <em>CFH</em> variants. This study highlights the great value of functional assays to appropriately assess the pathogenicity of <em>CFH</em> variants. </p><p><em>CFH</em> gene variants have been associated with both autosomal recessive and dominant forms of HUS [<a href="#rid39">39-45</a>]. Patients with homozygous variants have very low serum levels of CFH antigen, low serum C3 and CFB antigen levels, and a low CH50. However, most patients are heterozygous for the variant and have normal or only slightly decreased serum CFH and/or <em>C3</em> levels. As a result, normal factor H and C3 levels do not exclude the presence of a <em>CFH</em> variant. Interestingly, kidney survival is higher in patients with low CFH levels compared with those with normal levels of CFH. (See  <a class="medical medical_review" href="/z/d/html/3920.html" rel="external">"Overview and clinical assessment of the complement system"</a>.)</p><p>Although several studies have reported that HUS associated with <em>CFH</em> variants usually presents during infancy or early childhood [<a href="#rid39">39-41,46-49</a>], results from a French study showed that 25 of 59 patients with <em>CFH</em> variants initially presented after 20 years of age [<a href="#rid14">14</a>]. The disease either may be sporadic or clearly associated with a family history of disease. Severe hypertension is frequently observed. Hemolytic anemia is marked at disease onset and during relapses, with haptoglobin levels remaining low during the course of the disease.</p><p>Patients with <em>CFH</em> variants have the worst outcome of all the patients with complement-mediated HUS. The natural course of this disease results in 60 to 70 percent of patients progressing to end-stage kidney disease (ESKD) or death within one year of presentation [<a href="#rid34">34,50</a>]. In addition, there is a high rate of recurrent disease in patients who undergo kidney transplantation. (See <a class="local">'Kidney transplantation'</a> below.)</p><p class="headingAnchor" id="H10"><span class="h2">CD46</span><span class="headingEndMark"> — </span>Variants of the complement regulatory protein CD46 gene, previously known as membrane cofactor protein (MCP) [<a href="#rid51">51</a>], have also been implicated in familial HUS [<a href="#rid34">34,52-54</a>]. CD46 is a cofactor of CFI in the degradation of C3b and C4b. The aberrant protein either results in decreased cell surface levels of CD46 (most common) or an impaired ability to control alternative pathway complement activation on host cells [<a href="#rid55">55</a>]. HUS associated with CD46 deficiency is characterized by onset in early childhood, a favorable kidney outcome in most patients, frequent relapses, and a low rate of recurrence in the kidney allograft [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Factor I</span><span class="headingEndMark"> — </span>Variants of <em>CFI</em>, the cofactor for CD46 and factor H, are also associated with HUS [<a href="#rid50">50,57-59</a>]. CFI is a serine protease, which cleaves C3b and C4b in the presence of CFH and CD46. Most patients have heterozygous <em>CFI</em> variants, which result in either a quantitative or qualitative defect of the protein [<a href="#rid57">57,58</a>]. The prognosis of patients with HUS associated with <em>CFI</em> mutations is intermediate between those with HUS associated with <em>CD46</em> and those with <em>CFH</em> mutations. As an example, in two cohort studies, 50 to 60 percent of patients progressed to ESKD or died within two years of presentation [<a href="#rid50">50,59</a>], and in one of the studies, 30 percent of patients recovered from the initial presentation without disease recurrences [<a href="#rid59">59</a>]. Of note, in one of the cohort studies, 8 of 23 patients had an additional known genetic risk factor for HUS (ie, variant of <em>CD46</em>, <em>CFH</em>, <em>C3</em>, or <em>CFB</em>) [<a href="#rid59">59</a>]. Recurrent HUS occurs in 45 to 80 percent of patients, resulting in graft loss.</p><p class="headingAnchor" id="H12"><span class="h2">C3</span><span class="headingEndMark"> — </span>Heterozygous <em>C3</em> variants resulting in persistently low C3 levels have been identified in patients with HUS [<a href="#rid60">60-62</a>]. These variants are primarily located in the binding regions of C3b that interact with CFH, CD46, and complement receptor 1, and result in dysregulation of the alternative complement pathway [<a href="#rid60">60</a>]. Patients with <em>C3</em> variants typically develop severe disease, with one-half to two-thirds of patients progressing to ESKD within the first year following presentation. Recurrent disease is common in patients following kidney transplantation. In addition, there is an increase in the incidence of at-risk <em>CFH</em> and <em>CD46</em> haplotypes for HUS in these patients.</p><p class="headingAnchor" id="H29840315"><span class="h2">Factor B</span><span class="headingEndMark"> — </span>Gain of function variants of <em>CFB</em>, which either enhances the formation or delays the inactivation of C3bBb convertase, have been reported in 1 to 3 percent of cases of complement-mediated HUS [<a href="#rid63">63,64</a>]. Progression to ESKD occurs in 70 percent of patients. In the four reported cases of kidney transplantation, all four reported graft failure because of HUS recurrence.</p><p class="headingAnchor" id="H192646193"><span class="h2">Thrombomodulin</span><span class="headingEndMark"> — </span>Thrombomodulin is a cofactor in the initiation of the protein C anticoagulant pathway, which accelerates the inactivation of C3b by factor I. In a study of 152 patients with atypical HUS (ie, non-Shiga toxin-producing <em>E. coli</em> [STEC]-HUS), seven patients had six different heterozygous variants of the <em>THBD</em> gene [<a href="#rid65">65</a>]. In vitro studies demonstrated that the mutated <em>THBD</em> resulted in dysregulation of the complement system because it was less effective than normal thrombomodulin in converting C3b to its inactive form iC3b. (See  <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Activated protein C and protein S'</a>.)</p><p class="headingAnchor" id="H112362578"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H2314511847"><span class="h2">Presentation</span><span class="headingEndMark"> — </span>In all cases of HUS, clinical presentation includes the concurrent characteristic findings of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury due to complement activation. Other clinical findings include neurologic abnormalities (eg, seizures), gastrointestinal complications (eg, hemorrhage, pancreatitis), respiratory complications (respiratory failure, acute respiratory distress syndrome), and cardiac complications (eg, cardiomyopathy) [<a href="#rid66">66,67</a>].</p><p>Data from clinical registries have provided additional clinical information for complement-mediated HUS regarding age of presentation, penetrance of gene mutation for affected families, clinical triggers for acute episodes of complement activation, and complement levels [<a href="#rid14">14,34,50,68</a>]. However, data are often inconsistent as there is heterogeneity in the study population, and in the genes and coding sequences used for screening.</p><p class="bulletIndent1"><span class="glyph">●</span>Adult presentation ‒ Although earlier studies suggested that HUS due to genetic variants of the complement proteins was primarily a pediatric disorder [<a href="#rid34">34,50,68</a>], a French cohort of 214 patients reported that more than half of their cohort presented as adults (58 percent) [<a href="#rid14">14</a>]. In this study, genetic variants were demonstrated in 60 percent of the patients. However, in children with complement-mediated HUS, presentation typically occurred in young patients less than two years of age. Several studies also suggest that patients younger than six months who present with HUS are more likely to have complement-mediated disease than Shiga toxin-producing <em>E. coli </em>(STEC)-HUS.</p><p></p><p class="bulletIndent1">It remains unclear what effect, if any, specific variants have on the age of presentation. As noted above, initial studies had reported that most patients with complement factor H (<em>CFH</em>) variants present as infants or young children [<a href="#rid39">39-41,46-49</a>]. However, in the French study, 40 percent of patients with <em>CFH</em> variants presented after 20 years of age [<a href="#rid14">14</a>]. It does appear that patients with <em>CD46</em> variants (complement regulatory protein CD46) are more likely to present during childhood.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low penetrance ‒ A family history of HUS is obtained in approximately 20 to 30 percent of patients [<a href="#rid1">1,14</a>]. The penetrance of the disease is only approximately 50 percent, so that only half of the family members with the genetic mutation will manifest the disease. It has been shown that for the disease to manifest itself, other factors, such as a trigger (eg, infection) that activates complement, are typically present [<a href="#rid8">8,34</a>]. In other cases, multiple hits, such as the additional presence of antibodies to complement factor B or another genetic mutation, appear to increase the likelihood of disease expression.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antecedent trigger ‒ In most patients (70 to 80 percent), there is an antecedent trigger event that is thought to play a role in complement activation. In most patients, the trigger is an upper respiratory infection, however, a diarrheal prodrome has been observed in approximately one-quarter of patients. Pregnancy has also been reported as a trigger event in adolescents and adult women. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Previous episode of HUS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe hypertension.</p><p></p><p class="headingAnchor" id="H9168716"><span class="h2">Clinical course and outcome</span><span class="headingEndMark"> — </span>The clinical course and outcome vary depending on the affected complement component [<a href="#rid34">34,50</a>]. For example, patients with variants of the gene for CFH have a poor prognosis as most patients with this gene defect progress to end-stage kidney disease (ESKD) or death within the first year of presentation. In contrast, few patients harboring variants that affect CD46 progress to ESKD, although relapse is common [<a href="#rid50">50</a>]. (See <a class="local">'Genetic variants'</a> above.)</p><p class="headingAnchor" id="H2204745698"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>The diagnostic evaluation that differentiates complement-mediated HUS from other conditions with similar presentations, such as other forms of HUS, thrombocytopenia thrombotic purpura (TTP), and inborn errors of vitamin B12, is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">"Overview of hemolytic uremic syndrome in children", section on 'Evaluation to identify underlying etiology'</a> and  <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"</a>.)</p><p>In summary, studies that may differentiate complement-mediated HUS from other disorders include [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Screening for Shiga toxin-producing <em>E. coli</em> (STEC) to differentiate complement-mediated disease from STEC-HUS includes testing for Shiga toxins (eg, enzyme-linked immunosorbent assays [ELISA]) in the stool, stool cultures, and serologic testing for immunoglobulin M (IgM) and anti-lipopolysaccharide antibodies against the most frequent STEC serotypes. In addition, polymerase chain reaction (PCR) testing for Shiga toxin genes can also be performed. (See  <a class="medical medical_review" href="/z/d/html/6081.html" rel="external">"Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children", section on 'Testing for STEC infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the setting of concurrent serious infection, cultures of the blood, sputum, or cerebrospinal or pleural fluid may demonstrate an underlying serious pneumococcal infection, which is indicative of a diagnosis of pneumococcal-associated HUS rather than complement-mediated disease. (See  <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">"Overview of hemolytic uremic syndrome in children", section on 'Streptococcus pneumoniae'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complement levels ‒ A combination of abnormal complement tests, especially a decrease in both CFB and CH50 may be an important clue to support the diagnosis of complement-mediated HUS [<a href="#rid69">69</a>]. However, there is considerable overlap with normative values, and complement testing lacks sufficient sensitivity and specificity for diagnostic purposes. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with <em>C3</em> and factor B variants and those with antibodies to factor H typically have low plasma C3 levels but normal C4 levels. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with other variants (eg, variants to factor H, <em>CD46</em>, and thrombomodulin [<em>THBD</em>]), plasma C3 levels may be decreased or remain normal [<a href="#rid2">2,70</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In some patients, in whom the diagnosis is uncertain, a kidney biopsy may be performed. Complement-mediated HUS is characterized by arteriolar thrombotic microangiopathy  (<a class="graphic graphic_diagnosticimage graphicRef90803" href="/z/d/graphic/90803.html" rel="external">image 1</a>), perhaps accounting for the markedly increased blood pressure seen in some patients [<a href="#rid71">71</a>]. In contrast, most cases of STEC-HUS tend to have more glomerular than arteriolar involvement  (<a class="graphic graphic_diagnosticimage graphicRef90801" href="/z/d/graphic/90801.html" rel="external">image 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other studies that may be performed include assessing <em>ADAMTS13</em> function and screening for defective cobalamine metabolism. (See  <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">"Overview of hemolytic uremic syndrome in children", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/1338.html" rel="external">"Diagnosis of immune TTP", section on 'Reduced ADAMTS13 activity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnostic testing for complement dysregulation is performed for children with any of the following [<a href="#rid5">5</a>] (see <a class="local">'Diagnosis'</a> below):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Previous episode of HUS</p><p class="bulletIndent2"><span class="glyph">•</span>Family history of HUS</p><p class="bulletIndent2"><span class="glyph">•</span>Patient is less than one year of age and without evidence of a secondary cause (eg, pneumococcal or STEC infection)</p><p class="bulletIndent2"><span class="glyph">•</span>Episode of HUS during pregnancy or postpartum without evidence of a secondary cause </p><p></p><p class="headingAnchor" id="H738840"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of complement-mediated HUS is based upon the classical triad microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury, plus demonstration of complement dysregulation, either due to gene variants of complement proteins or antibodies to complement factors. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to perform testing</strong> – Diagnostic testing for complement-mediated HUS is appropriate in patients with HUS who have any of the following [<a href="#rid5">5,72</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Positive family history of HUS</p><p class="bulletIndent2"><span class="glyph">•</span>Previous episode of HUS</p><p class="bulletIndent2"><span class="glyph">•</span>Early presentation (ie, within the first six to twelve months of age)</p><p class="bulletIndent2"><span class="glyph">•</span>Presentation during pregnancy or postpartum</p><p class="bulletIndent2"><span class="glyph">•</span>Severe clinical course with no identified underlying cause (see  <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">"Overview of hemolytic uremic syndrome in children", section on 'Evaluation to identify underlying etiology'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tests to perform</strong> – Diagnostic testing for complement-mediated HUS includes complement genotyping and testing for antibodies to complement proteins. The minimum set of genes that should be evaluated includes <em>CFH</em>, <em>CD46</em>, <em>CFI</em>, <em>C3</em>, <em>CFB</em>, <em>THBD</em>, <em>CFHR1</em>, <em>CFHR5</em>, and<em> DGKE </em>[<a href="#rid2">2</a>]<em>.</em> Because of the frequent concurrence<em> </em>of genetic risk factors, testing should also<em> </em>include genotyping for the risk haplotypes <em>CFH-H3</em> and <em>MCP</em>.</p><p></p><p class="bulletIndent1">Testing for antibodies and genetic variants may not be available in all settings. Laboratories that offer complement genotyping for complement-mediated HUS can be found from the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2FGeneTests%2Flab%2Fdisease%2Fatypical+hus%3Fdb%3Dgenetests%26search_param%3Dcontains&amp;token=oNz6QKpDtHy%2BIr7LKk2pP66SxGN%2BcNNVbblZmB5n8QcHJnCJKoRRtKxco8XiH%2BkhSZWtjCCPEiuOKf6wyS%2BRqlOhOwso4i821huqgbD%2B2C7u%2Fe4Xj2F4JtkgTQx7Zj%2FPrwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=6084" target="_blank">National Center for Biotechnology Information website</a>. </p><p></p><p class="bulletIndent1">As noted above, although many patients with complement-mediated HUS will have low C3 or C4 levels, normal plasma levels of C3, C4, CFB, CFH, and CFI do not exclude the diagnosis of complement-mediated HUS. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="headingAnchor" id="H192646912"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of complement-mediated HUS includes HUS due to other causes and conditions that also present concomitantly with anemia, thrombocytopenia, and acute kidney injury. Further evaluation including history and additional laboratory tests may differentiate complement-mediated HUS from these other disorders. (See  <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">"Overview of hemolytic uremic syndrome in children", section on 'Evaluation to identify underlying etiology'</a> and  <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"</a>.)</p><p class="headingAnchor" id="H192646920"><span class="h2">Other forms of HUS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Shiga toxin-producing <em>E. coli</em> (STEC)-HUS accounts for 90 percent of pediatric cases of HUS. It is differentiated from complement-mediated HUS based on demonstrating a recent exposure to STEC. Screening for STEC-HUS is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6081.html" rel="external">"Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children", section on 'Testing for STEC infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pneumococcal-associated HUS occurs in a patient with evidence of a pneumococcal infection (eg, pneumonia, sepsis, or meningitis), which is confirmed by a positive culture of blood and/or other pertinent tissues. (See  <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">"Overview of hemolytic uremic syndrome in children", section on 'Streptococcus pneumoniae'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other rare noninfectious secondary causes of HUS include drug toxicity, especially in patients with cancer or in bone marrow or solid organ transplant recipients, or are associated with pregnancy or autoimmune disease. It remains uncertain whether these clinical settings may act as triggers for activation of the complement pathway in susceptible individuals with genetic variants in complement proteins. (See  <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">"Overview of hemolytic uremic syndrome in children", section on 'Acquired non-infectious causes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inborn error of cobalamin C metabolism is a rare cause of HUS, especially in young infants (one to three months of age). The diagnosis is suggested by amino acid and organic acid chromatography findings of a marked increase of homocysteine and a low level of methionine in the plasma, and a very high urinary excretion of homocysteine and methylmalonic acid. (See  <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">"Overview of hemolytic uremic syndrome in children", section on 'Acquired non-infectious causes'</a>.)</p><p></p><p class="headingAnchor" id="H192646996"><span class="h2">Thrombotic thrombocytopenic purpura</span><span class="headingEndMark"> — </span>Thrombotic thrombocytopenic purpura (TTP) is due to deficient activity of the Von Willebrand factor cleaving protease. Pediatric TTP is rare and is usually due to variants of the <em>ADAMTS13</em> gene. Affected children usually present at birth with hemolytic anemia and thrombocytopenia. Kidney involvement often occurs later in life and has a progressive course. TTP is distinguished from HUS by abnormally low ADAMTS13 activity. The mainstay of initial treatment for TTP is plasma exchange, as untreated patients progress to kidney failure and further neurologic deterioration, and are at risk for cardiac ischemia and death. (See  <a class="medical medical_review" href="/z/d/html/1338.html" rel="external">"Diagnosis of immune TTP", section on 'Reduced ADAMTS13 activity'</a> and  <a class="medical medical_review" href="/z/d/html/101504.html" rel="external">"Hereditary thrombotic thrombocytopenic purpura (hTTP)"</a> and  <a class="medical medical_review" href="/z/d/html/1344.html" rel="external">"Immune TTP: Initial treatment", section on 'Therapeutic plasma exchange'</a>.)</p><p>Perhaps a further challenge in differentiating TTP from HUS is that partial ADAMTS13 deficiency may occur in patients with complement-mediated HUS. This was illustrated in a study of patients with complement-mediated HUS based on clinical criteria that reported several of the 13 patients with variant in complement genes also had mild to moderated reduction of ADAMTS13 activity due to single nucleotide polymorphism of the <em>ADAMTS13</em> gene [<a href="#rid73">73</a>]. The authors concluded that partial ADAMTS13 deficiency may occur in patients with complement-mediated HUS, and <em>ADAMTS13</em> activity should be evaluated in affected patients.</p><p class="headingAnchor" id="H15"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H3603740876"><span class="h2">Overview</span><span class="headingEndMark"> — </span>The initial management of complement-mediated HUS is supportive and similar to the approach used for Shiga toxin-associated HUS. (See  <a class="medical medical_review" href="/z/d/html/6097.html" rel="external">"Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children", section on 'Supportive therapy'</a>.)</p><p>In addition to supportive care measures, the management of complement-mediated HUS may include [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Plasma exchange or infusion</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">Eculizumab</a>, a monoclonal antibody to C5 that blocks the terminal complement cascade</p><p class="bulletIndent1"><span class="glyph">●</span>Kidney or combination kidney-hepatic transplantation</p><p></p><p>The following sections regarding the care of patients with complement-mediated HUS are consistent with a published international consensus approach to the management of complement-mediated HUS in children [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H264004134"><span class="h2">Supportive care</span><span class="headingEndMark"> — </span>Supportive therapy includes [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Red blood cell transfusions for anemia when clinically indicated (eg, hemoglobin level in children is &lt;6 g/dL or hematocrit &lt;18 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Platelet transfusion for patients who have significant clinical bleeding or if an invasive procedure is required.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Appropriate fluid and electrolyte management to maintain adequate intravascular volume and correct/avoid electrolyte abnormalities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stopping nephrotoxic drugs or those that are implicated in the etiology of HUS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initiation of dialysis therapy in patients with symptomatic uremia, azotemia (defined as a blood urea nitrogen &gt;80 mg/dL [29 mmol/L]), severe fluid overload, or electrolyte abnormality that is refractory to medical therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Provision of adequate nutrition.</p><p></p><p class="headingAnchor" id="H2885272497"><span class="h2">Patients with complement antibodies</span><span class="headingEndMark"> — </span>The management of patients with Complement factor H (CFH) antibodies is challenging and evolving due to the reported beneficial effects of initial therapy with <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a>, however limited data are based on small case series [<a href="#rid26">26</a>]. Prior to the introduction of eculizumab, the initial management of patients with CFH antibodies included supportive care with plasmapheresis or plasma exchange, followed by immunosuppressive therapy directed to inhibiting further production of antibodies and preventing relapses.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Our approach</strong> – Based on the available evidence cited below, we begin treatment with plasma exchange to rapidly remove circulating anti-CFH antibodies, followed by immunosuppressive therapy to ensure reduced production of anti-CFH antibodies [<a href="#rid29">29,74-76</a>]. Immunosuppression ensures reduced production of anti-CFH antibodies and includes oral corticosteroids with or without the addition of intravenous (IV) <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">cyclophosphamide</a>, <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a>, or <a class="drug drug_pediatric" data-topicid="12624" href="/z/d/drug information/12624.html" rel="external">mycophenolate</a> mofetil (MMF). </p><p></p><p class="bulletIndent1">Although data are limited, plasma exchange plus immunosuppressive therapy have been successful measures in patients with CFH antibodies [<a href="#rid21">21-23,25,75,77</a>]. In contrast, treatment with intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">immune globulin</a> (IVIG) does not appear to be beneficial [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunosuppressive regimens</strong> – Protocols following plasma exchange include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A regimen that consists of induction therapy of oral <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a> (1 mg/kg per day for four weeks and followed by alternate days for four weeks) with either two to five doses of IV <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">cyclophosphamide</a> or two doses of IV <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a>, and maintenance treatment with tapering doses of prednisone and <a class="drug drug_pediatric" data-topicid="12624" href="/z/d/drug information/12624.html" rel="external">mycophenolate</a> mofetil or <a class="drug drug_pediatric" data-topicid="12923" href="/z/d/drug information/12923.html" rel="external">azathioprine</a> for 18 to 24 months [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use of pulses of <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">cyclophosphamide</a>, oral <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a>, and plasma exchange resulted in sustain remission for three children. <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">Rituximab</a> was also used in one other patient to treat recurrent relapses [<a href="#rid75">75,76</a>]. In these four patients, sustained remission was achieved up to six years. Although anti-CFH Ab titer decreased, it remained detectable during remission.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of </strong><strong>eculizumab</strong> – <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">Eculizumab</a> may be considered during the acute stage, particularly if plasma exchange is not available, if severe neurologic or cardiac illness is present, or if the patient does not respond to intensive plasma exchange.</p><p></p><p class="bulletIndent1">Alternatively, <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> may be considered as a first-line treatment with the possibility of adding corticosteroids and/or MMF in an attempt to reduce antibody titer. However, the safety efficacy profiles and cost-effectiveness of approaches combining few plasma exchanges and immunosuppressive therapy, or long-term eculizumab therapy, have to be determined.</p><p></p><p class="bulletIndent1">Support for <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> therapy without immunosuppression is based upon case reports and a small case series [<a href="#rid26">26,78,79</a>]. In a series of 17 children with CFH antibodies, including seven who had concomitant HUS genetic variants, immunosuppressive therapy was not given, because of concerns over treatment-associated complications [<a href="#rid26">26</a>]. The outcome varied based on management. All patients who received eculizumab recovered kidney function and achieved sustained remission. Two patients treated only with supportive care developed end-stage kidney disease (ESKD). Four of 11 patients treated with plasma exchange recovered kidney function. The authors concluded that based on these results, their clinical practice is to initiate only eculizumab therapy for treatment of CFH autoantibody-mediated HUS and not include plasma exchange or immunosuppressive therapy. </p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">Eculizumab</a> is discussed in greater detail below. (See <a class="local">'Complement blockade (eculizumab)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renal transplantation</strong> – Although data on the outcome of kidney transplantation is limited in patients with CFH antibodies, one-quarter to one-third of patients have allograft loss due to recurrent disease [<a href="#rid74">74</a>]. The risk of recurrence increases with high antibody titers and if there is a concomitant variant in genes encoding CFH, C3, or CFB. For patients at-risk for disease recurrence (antibody titers &gt;1000 AU/mL and/or variants in these specific complement protein), additional preventive measures (eg, <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> or plasma therapy) should be provided prior to transplantation. (See <a class="local">'Transplantation'</a> below.)</p><p></p><p class="headingAnchor" id="H1311837247"><span class="h2">Patients with genetic variants</span></p><p class="headingAnchor" id="H181861875"><span class="h3">Complement blockade (eculizumab)</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">Eculizumab</a> is the first-line treatment for patients with severe forms of compliment-mediated HUS. </p><p><a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">Eculizumab</a> a humanized monoclonal antibody that binds to complement protein C5, blocking its cleavage, thereby preventing the production of the terminal complement components C5a and the membrane attack complex (MAC) C5b-9 [<a href="#rid80">80</a>]. This results in reduction of the terminal-complement activation that occurs in patients with complement-mediated HUS, thereby reducing endothelial damage, thrombosis, and subsequent kidney injury. (See <a class="local">'Pathogenesis'</a> above.)</p><p class="headingAnchor" id="H2293084988"><span class="h4">Indications and timing</span><span class="headingEndMark"> — </span>We recommend <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> in patients in with severe forms of complement-mediated HUS (eg, patients with <em>CFH</em> and complement factor I [<em>CFI</em>] variants). Our strong recommendation despite the lack of prospective clinical trials and despite the known potential for adverse events (ie, severe infections) is based upon observational studies demonstrating a large magnitude of effect in reducing progression to ESKD and death. These data are discussed below. (See <a class="local">'Efficacy'</a> below.)</p><p>Treatment with <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> should be started as soon as possible, ideally within the first 48 hours of admission.</p><p><a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">Eculizumab</a> may not be available in all settings due to prohibitive cost [<a href="#rid81">81-83</a>]. Plasma therapy is often used in such cases. However, even in resource-limited areas, eculizumab should be considered in patients who fail to respond to plasma therapy, who have life-threatening disease (seizure, heart failure), and serious complications of plasma [<a href="#rid83">83</a>]. (See <a class="local">'Plasma therapy'</a> below.)</p><p>While <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> is generally not considered a first-line therapy in patients with CFH antibodies, it is a reasonable treatment option for severely affected patients, as discussed above. (See <a class="local">'Patients with complement antibodies'</a> above.)</p><p class="headingAnchor" id="H262427508"><span class="h4">Pretreatment evaluation and vaccination</span><span class="headingEndMark"> — </span>Testing for anti-CFH antibodies is the only urgent complement investigation required, since other treatment options are available for patients with HUS due to antibodies to CFH [<a href="#rid74">74</a>]. (See <a class="local">'Complement antibodies'</a> above and <a class="local">'Plasma therapy'</a> below.)</p><p>Patients should receive vaccinations for <em>Neisseria meningitis</em>, <em>S. pneumoniae </em>and <em>Haemophilus influenza type b</em>, since there is a risk of developing serious infections due to these pathogens while on <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a>. When possible, vaccination should be performed prior to the initiation of eculizumab therapy. However, this may not be possible in some patients due to the severity of the initial presentation. For such patients, vaccination should be administered once the patient is stable. (See <a class="local">'Prevention of infectious complications'</a> below.) </p><p class="headingAnchor" id="H9171795"><span class="h4">Dosing</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">Eculizumab</a> is administered as an intravenous infusion. Induction dosing of eculizumab is based on patient body weight as follows [<a href="#rid84">84</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>5 to &lt;10 kg – 300 mg, one weekly dose</p><p class="bulletIndent1"><span class="glyph">●</span>10 to &lt;20 kg – 600 mg, one weekly dose</p><p class="bulletIndent1"><span class="glyph">●</span>20 to &lt;30 kg – 600 mg, two weekly doses</p><p class="bulletIndent1"><span class="glyph">●</span>30 to &lt;40 kg – 600 mg, two weekly doses</p><p class="bulletIndent1"><span class="glyph">●</span>≥40 kg – 900 mg, four weekly doses</p><p></p><p>Maintenance dosing based on patient body weight as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>5 to &lt;10 kg – 300 mg every three weeks, starting week two</p><p class="bulletIndent1"><span class="glyph">●</span>10 to &lt;20 kg – 300 mg every two weeks, starting week two</p><p class="bulletIndent1"><span class="glyph">●</span>20 to &lt;30 kg – 600 mg every two weeks, starting week three</p><p class="bulletIndent1"><span class="glyph">●</span>30 to &lt;40 kg – 900 mg every two weeks, starting week three</p><p class="bulletIndent1"><span class="glyph">●</span>≥40 kg – 1200 mg every two weeks, starting week five</p><p></p><p>Of note, the doses for young children were calculated from a pharmacokinetic model derived from adult data because there are <strong>no</strong> data in children. In some children, the above dosing protocol does not completely blocked complement activation, and in these patients, dosing has been increased. If <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> is used in young children, complement activity should be assessed by measuring CH50. (See  <a class="medical medical_review" href="/z/d/html/3920.html" rel="external">"Overview and clinical assessment of the complement system", section on 'CH50'</a>.)</p><p>The use of functional complement testing has been used to monitor and modify <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> therapy [<a href="#rid85">85,86</a>]. </p><p class="headingAnchor" id="H1123864528"><span class="h4">Monitoring</span><span class="headingEndMark"> — </span>During initial treatment, monitoring consists of frequent assessment of kidney function (ie, urinalysis, blood urea nitrogen [BUN], creatinine) and hematologic testing (ie, complete blood count [CBC] with platelet count).</p><p>In addition, monitoring of complement activity is required during <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> treatment [<a href="#rid2">2,86,87</a>]. CH50 should be &lt;10 percent for a complete suppression. However, CH50 cannot be used for patients with complete CFH deficiency. One report demonstrated that using a global complement functional test (Wieslab) and maintaining a complement activity at &lt;30 percent appears to safely reduce the frequency of eculizumab administration while keeping the disease in remission [<a href="#rid87">87</a>]. </p><p>Although not widely available, <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> blood levels appear to be the optimal way to monitor the treatment. Levels at 100 mg/mL or over 100 mg/mL markedly reduce CH50 activity while values less than 50 mg/mL do not [<a href="#rid5">5</a>]. However, interpretation of eculizumab levels is difficult since the assays differ from each other, and all detect both bound and unbound drug [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/3920.html" rel="external">"Overview and clinical assessment of the complement system", section on 'Complement measurement'</a> and  <a class="medical medical_review" href="/z/d/html/3920.html" rel="external">"Overview and clinical assessment of the complement system", section on 'CH50'</a>.)</p><p>The frequency between dosing can be extended if adequate complement blockage is maintained [<a href="#rid87">87</a>]. </p><p class="headingAnchor" id="H481200298"><span class="h4">Adverse effects</span><span class="headingEndMark"> — </span>Treatment with <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> is associated with life-threatening and fatal meningococcal infections with a reported annual rate of 0.5 percent. (See  <a class="medical medical_review" href="/z/d/html/7163.html" rel="external">"Treatment and prognosis of paroxysmal nocturnal hemoglobinuria", section on 'Eculizumab'</a>.). </p><p>In a report from the Centers for Disease Control and Prevention (CDC), 16 cases of meningococcal disease were identified in <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> recipients in the United States between 2008 and 2016, including patients who had received at least one dose of meningococcal vaccine [<a href="#rid88">88</a>]. (See  <a class="medical medical_review" href="/z/d/html/1298.html" rel="external">"Epidemiology of Neisseria meningitidis infection", section on 'Use of eculizumab'</a>.)</p><p>Other reported serious adverse events in patients with complement-mediated HUS treated with <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> include hypertension, asymptomatic bacteremia, influenza, peritonitis, and venous sclerosis at the infusion site [<a href="#rid89">89</a>].</p><p class="headingAnchor" id="H2988581533"><span class="h4">Prevention of infectious complications</span><span class="headingEndMark"> — </span>Patients should receive vaccinations for <em>Neisseria meningitis</em> and for <em>S. pneumoniae </em>and <em>Haemophilus influenza type b</em>, as they are at risk of developing serious infections due to these pathogens. If therapy is given to an unvaccinated patient, pneumococcal vaccination should be administered as soon as possible, and prophylactic antibiotic coverage given for two weeks. Prophylactic antibiotic coverage should also be given to reduce the risk of <em>Neisseria meningitis</em> B infection while patients are receiving <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a>, as the currently available <em>Neisseria </em>serogroup B vaccines may not provide adequate protection [<a href="#rid90">90</a>]. Prevention of meningococcal infection, including vaccination and prophylactic antibiotics is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1274.html" rel="external">"Treatment and prevention of meningococcal infection", section on 'Patients receiving C5 inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function", section on 'Daily antibiotic prophylaxis'</a>.)</p><p>In the United States, prescribers of <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> are required to enroll in a registration program to certify that they counsel patients and provide educational materials about the risks of eculizumab and agree to promptly report cases of meningococcal infection. Enrollment and additional information are provided by the manufacturer (1-888-765-4747).</p><p>Although vaccination for <em>Neisseria meningitis</em> and for <em>S. pneumoniae </em>and <em>Haemophilus influenza type b </em>are recommended, a review by <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.hc-sc.gc.ca%2Fdhp-mps%2Fmedeff%2Freviews-examens%2Fsoliris-bexsero-eng.php&amp;token=EPa3045vII57zWLxah07edEKclXuh4z89WoNj0My2ld3tp2WL4L%2FT2Cw6Dz6%2FrEs3yfWkEmJF%2FFkqeqE5GKnuAKKu%2BUARANROS0l8j27ymM%3D&amp;TOPIC_ID=6084" target="_blank">Health Canada</a> reported an increased risk of hemolytic anemia following receipt of the multicomponent <a class="drug drug_pediatric" data-topicid="99754" href="/z/d/drug information/99754.html" rel="external">meningococcal serogroup B vaccine</a> (Bexsero, MenB-4C) among patients who were already being treated with <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> [<a href="#rid91">91</a>]. To minimize the risk of hemolysis, if possible, vaccination should be performed prior to the initiation of eculizumab therapy. For some patients, this may not be possible due to the severity of their initial presentation. In such cases, vaccination should be administered when patients are stable, and their disease is well controlled. (See  <a class="medical medical_review" href="/z/d/html/6022.html" rel="external">"Prevention of <i>Haemophilus influenzae</i> type b infection", section on 'Routine childhood immunization in the United States'</a> and  <a class="medical medical_review" href="/z/d/html/6053.html" rel="external">"Pneumococcal vaccination in children"</a>.)</p><p class="headingAnchor" id="H609016720"><span class="h4">Discontinuation</span><span class="headingEndMark"> — </span>Based on observational studies, it appears that <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> therapy can be discontinued in selected patients who have had a favorable response to therapy [<a href="#rid92">92-98</a>]. However, some patients may relapse, so ongoing close monitoring (ie, frequent urinalysis and weekly CBC) is required so eculizumab therapy can be reinitiated as relapsed patients respond to resumption of therapy [<a href="#rid3">3,96,98</a>]. It appears that the risk of relapse after eculizumab withdrawal differs based on the underlying genetic variant with higher relapse rates seen in patients with germline variants for CFH, MCP, CFI and CD46 [<a href="#rid94">94,98</a>]. </p><p>Further studies are needed to further define the optimal timing of withdrawal of <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> therapy and the patient population in whom therapy can be safely discontinued [<a href="#rid97">97,99,100</a>]. Until such data are available, the decision to withdraw eculizumab therapy should be made in conjunction with a clinician with expertise in managing patients with complement-mediated HUS.</p><p class="headingAnchor" id="H336509876"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>Based upon the available observational data, <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> therapy is associated with dramatic improvements in kidney function and possible improvement in survival among patients with severe forms of complement-mediated HUS, particularly those with <em>CFH</em> and <em>CFI</em> genetic variants [<a href="#rid9">9,89,101-111</a>].</p><p>The US Food and Drug Administration (FDA) granted accelerated approval for the use of <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> for the treatment of complement-mediated HUS based on review of two small prospective studies [<a href="#rid112">112</a>]. In both studies, identification of a complement gene variant was not required, but the studies excluded patients with <em>ADAMTS13</em> activity &lt;5 percent of normal, those who had evidence of STEC-HUS, and those with prior eculizumab treatment. The following findings were noted in these early studies [<a href="#rid89">89</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In the first study of 17 pediatric and adult patients who were refractory to plasma therapy, four of five patients who required dialysis at baseline were able to discontinue dialysis therapy while receiving <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> and remained off dialysis over the two-year follow-up period. For 10 patients, there was an improvement in kidney function with an increase of at least 15 mL/min per 1.73 m<sup>2</sup> in the estimated glomerular filtration rate (eGFR) that was sustained over the two-year follow-up period. Two patients, including one who discontinued eculizumab therapy, progressed to ESKD and began dialysis therapy.</p><p></p><p class="bulletIndent1">Normal platelet counts and lactate dehydrogenase levels, indicating thrombotic microangiopathy (TMA) event-free status, were observed in 14, 13, and 15 patients at 26 weeks, 1 year, and 2 years of follow-up, respectively. Thirteen patients were found to have complement variants or antibodies to complement factor H. At the end of two years, 11 patients remained on <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The second study involved 20 patients who were maintained on plasma therapy. Administration of <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> was associated with a discontinuation of plasma therapy in all patients, normalization of hematological parameters in 18 of the 20 patients that was maintained at two-year follow-up, and improved kidney function in three patients (increase of eGFR &gt;15 mL/min per 1.73 m<sup>2</sup>). For the two patients who were on dialysis at baseline, there was no improvement, as one remained on dialysis and the other remained on dialysis until undergoing kidney transplantation. In addition, another patient required dialysis during a hospitalization for intestinal hemorrhage, and subsequently died. Fourteen patients were found to have complement variants or antibodies to complement factor H. At the end of two years, 18 patients remained on eculizumab therapy.</p><p></p><p>Subsequent studies continue to demonstrate the benefits of <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> in children and adults with atypical HUS [<a href="#rid109">109,111,113,114</a>]. In the largest study, which included 72 patients with atypical HUS treated with eculizumab, kidney function improved dramatically on treatment (ie, eGFR increased by a median of 74 mL/min/m<sup>2</sup>; proteinuria resolved in nearly all cases, and the proportion of patients requiring dialysis decreased from 38 to 10 percent) [<a href="#rid111">111</a>]. There was only one death in this cohort over a median follow-up of 21 months (mortality rate 1.4 percent). This is considerably lower compared with studies published before eculizumab was available, in which mortality rates were as high as 40 to 50 percent in some studies, depending upon the specific genetic variants studied. (See <a class="local">'Clinical course and outcome'</a> above and <a class="local">'Genetic variants'</a> above.) </p><p>Hematologic normalization and recovery of kidney function has been observed in the overwhelming majority of patients treated with <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> during their first episode and subsequent episodes of HUS [<a href="#rid109">109,111,113,114</a>], including those who have undergone kidney transplantation [<a href="#rid106">106</a>]. (See <a class="local">'Kidney transplantation'</a> below.)</p><p class="headingAnchor" id="H4190314093"><span class="h3">Other C5 blocking agents</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="127141" href="/z/d/drug information/127141.html" rel="external">Ravulizumab</a> is a long-acting C5 inhibitor that was engineered from <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a>. It has been reported to be effective in the treatment of complement-mediated HUS in adults and small pediatric case series including one report in which patients were switched from eculizumab to ravulizumab [<a href="#rid115">115-118</a>]<strong>. </strong>In the United States, ravulizumab is available only through a restricted Risk Evaluation and Mitigation Strategy (REMS) program. </p><p class="headingAnchor" id="H121904457"><span class="h3">Plasma therapy</span><span class="headingEndMark"> — </span>Plasma therapy as a first-line therapy has largely been replaced by <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a>. However, plasma therapy is still used in resource-limited areas where eculizumab is not widely available [<a href="#rid83">83</a>]. </p><p>Plasma therapy appears to be less effective compared with <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a>; only approximately one-half of patients with complement-mediated HUS respond to plasma exchange with both kidney (normal or improved kidney function) and complete hematologic recovery (ie, no evidence of hemolysis and a normal platelet count) [<a href="#rid8">8</a>]. Thus, even in resource-limited areas, efforts to initiate eculizumab therapy should be made for patients with any of the following [<a href="#rid83">83</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Life-threatening complications of HUS (seizures, coma, heart failure)</p><p class="bulletIndent1"><span class="glyph">●</span>Serious complications from plasma therapy, including no vascular access</p><p class="bulletIndent1"><span class="glyph">●</span>No response to plasma therapy within 10 days </p><p class="bulletIndent1"><span class="glyph">●</span>Confirmed diagnosis of a high-risk complement genetic variant (eg, <em>CFH</em> or <em>CFI</em>)</p><p></p><p>Plasma therapy consists of either plasma exchange (plasmapheresis) or infusion of fresh frozen plasma (FFP). Although clinical trials are lacking, most experts in the field advocate for plasmapheresis rather than FFP infusions as a means to both remove defective mutant proteins and antibodies to CFH, and restore normal functioning complement proteins [<a href="#rid9">9,74</a>]. In addition, plasmapheresis avoids the risk of volume overload and hypertension in patients with acute kidney injury.</p><p>Most patients who have responded to an initial treatment with plasma infusions or plasma exchange should be switched to <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> for subsequent therapy. This strategy offers the best chance of complete kidney recovery. However, patients who are in full remission and have normal kidney function under plasma therapy without catheter complications nor plasma intolerance may remain on this therapy [<a href="#rid5">5</a>].</p><p>The response to plasma treatment varies depending upon the affected complement component [<a href="#rid9">9,34</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><em>CFH</em> variants – In patients with <em>CFH</em> variants, plasma therapy results in complete or partial remission in approximately two-thirds of patients. This has improved outcome with a decrease in mortality, and if initiated early in the course of the disease, preservation of kidney function over months and years [<a href="#rid119">119-122</a>]. Those who fail to respond generally progress to ESKD. In addition, resistance to long-term plasma therapy has been reported in patients [<a href="#rid123">123</a>]. Maintenance plasma therapy appears to be superior to intermittent plasma therapy given only during acute episodes of recurrent disease. However, the overall rate of complete kidney recovery is only five percent. Because long-term plasmapheresis is expensive and requires central venous access, efforts are underway to develop a purified human plasma-derived CFH concentrate, which can be given in a small volume.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>CFI</em> variants – The response to plasma therapy is often inadequate, with only approximately one-quarter of patients with <em>CFI</em> variants achieving remission.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD46 deficiency – Plasma therapy provides no additional benefit in patients with CD46 deficiency, as CD46 is a transmembrane protein, and most of these patients recover fully without plasma therapy [<a href="#rid8">8,50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Limited data suggest a positive benefit of plasma therapy in patients with gene variants of <em>C3</em> and thrombomodulin (<em>THBD</em>). However, data are insufficient to determine whether plasma therapy is beneficial in patients with gene variants of complement factor B (<em>CFB</em>).</p><p></p><p>Use of plasmapheresis in patients with CFH antibodies is discussed above. (See <a class="local">'Patients with complement antibodies'</a> above.)</p><p>Complications of plasma exchanges include hypotension, catheter-related complications (infection, thrombosis), and anaphylactic reactions to plasma. (See  <a class="medical medical_review" href="/z/d/html/7942.html" rel="external">"Therapeutic apheresis (plasma exchange or cytapheresis): Complications"</a>.)</p><p class="headingAnchor" id="H264004563"><span class="h2">Transplantation</span></p><p class="headingAnchor" id="H264004591"><span class="h3">Kidney transplantation</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complement genotyping and risk stratification</strong> ‒ Patients with HUS prior to transplantation should undergo complement genotyping to determine whether there is an underlying gene variant. In addition, genotyping will identify recipients who are at greatest risk for recurrent disease. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with variants in genes for <em>CFH</em>, <em>CFI</em>, or <em>C3</em> who fail to respond to plasma therapy, and/or have relapsing disease are likely to progress to ESKD [<a href="#rid34">34</a>]. In these patients, the outcome of kidney transplantation is poor because recurrence of disease occurs in 50 percent of the transplanted kidneys, and graft failure occurs in 90 percent of those with recurrent disease [<a href="#rid9">9,34,124-126</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Limited data suggest a more favorable outcome of renal transplantation in patients with variants of <em>CD46</em> or in those with disease due to antibodies to factor H, provided the autoantibodies to CFH are absent at the time of transplantation [<a href="#rid53">53,54,77,124</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Living donor evaluation</strong> ‒ Genetic testing of the donor is performed to ensure that the same mutation is not present in the potential living donor due to the low penetrance of disease [<a href="#rid127">127,128</a>]. In our practice, a living-related transplantation is only performed if both the donor and the recipient have given informed consent, testing confirms that the donor does not have the underlying gene variant, and for recipients at risk for recurrent disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of disease recurrence</strong> ‒ Patients with a low risk of recurrence do not need a preventive treatment. These include those with isolated membrane cofactor protein or <em>DGKE</em> variants and patients with anti-complement factor H antibodies in whom the level of antibodies decreased to a negative level long-term. (See <a class="local">'Complement antibodies'</a> above.)</p><p></p><p class="bulletIndent1">All other patients receive preventive therapy (eg, <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> and plasma therapy) at the time of and after transplantation to reduce the risk of disease recurrence. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">Eculizumab</a> – Eculizumab therapy is our preferred intervention to prevent recurrent disease in renal transplant recipients with an identified variant in <em>CFH</em>, <em>CFI</em>, <em>C3</em>, or <em>CFB</em>, or in those with a previous post-transplant episode of recurrent disease [<a href="#rid103">103,113,127,129-131</a>]. Eculizumab may also be an option for patients with a moderate risk of recurrence. However, as noted above, this therapy may not be available in some settings because of the prohibitive cost of eculizumab. Another alternative in patients with complement autoantibodies is the addition of <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a> therapy to the immunosuppressive regimen, which was used successfully in one case report of a patient with CFH antibodies and deletion of <em>CFHR1</em> and <em>CFHR3</em> genes [<a href="#rid132">132</a>]. The optimal duration of eculizumab therapy remains unknown.I In our practice, we continue long-term eculizumab therapy in high-risk patients throughout the lifespan of the allograft unless combined liver-kidney transplantation is undertaken. (See <a class="local">'Combined liver-renal transplantation'</a> below.)</p><p></p><p class="bulletIndent2">Pregnant women with kidney transplantation for complement-mediated HUS (aHUS) have been successfully managed with <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> therapy [<a href="#rid133">133</a>]. In these patients, eculizumab dosing requires adjustment during pregnancy to reach optimal eculizumab levels, which ensure effective complement blockade, and close monitoring of hemolysis biomarkers.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Plasma therapy</strong>– If plasma therapy is used to prevent recurrent disease, the first exchange is performed a few hours prior to transplantation. After transplantation, plasma therapy is initially performed daily followed by decreasing frequency [<a href="#rid134">134</a>]. However, prophylactic plasma therapy may fail to prevent recurrence and may mask clinical signs of recurrence [<a href="#rid126">126</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alternative approach using living related donors</strong> – In a case series of 17 patients, a strategy employed the use of living kidney donors, low-dose <a class="drug drug_pediatric" data-topicid="12822" href="/z/d/drug information/12822.html" rel="external">tacrolimus</a> and strict blood pressure control. In this cohort that included 16 patients with a variant in genes encoding complement factors, only one patient had a recurrence of HUS, which was successfully treated with <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> [<a href="#rid135">135</a>]. Although the cohort size is limited and the follow-up is short, these results suggest that a rescue approach is a reasonable alternative to the more costly eculizumab prophylactic strategy [<a href="#rid136">136</a>]. Further, studies are needed to determine whether a rescue strategy is a feasible option. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of recurrent disease</strong> – <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">Eculizumab</a> has been shown to be beneficial in patients with post-transplant recurrent disease [<a href="#rid102">102,106,107,113,127,137-139</a>]. In contrast, plasma therapy has failed to improve graft survival in renal transplant recipients with recurrent disease. </p><p></p><p class="headingAnchor" id="H264004612"><span class="h3">Combined liver-renal transplantation</span><span class="headingEndMark"> — </span>Liver transplantation may be a curative intervention for severe complement-mediated HUS for patients with variants of <em>CFH</em>, <em>CFI</em>, <em>CFB</em>, and <em>C3</em>, which are proteins that are synthesized in the liver. In addition, combined liver-renal transplantations have been proposed in patients with ESKD in whom there is a high likelihood of recurrent disease [<a href="#rid134">134</a>]. However, data are limited regarding patient outcome. A 2014 review reported 25 patients with complement-mediated HUS underwent combined liver-renal transplantation [<a href="#rid140">140</a>]. All five children who did not have a preparative regimen for complement regulation (eg, plasma therapy or <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a>) suffered fatal complications, presumably due to uncontrolled complement activation. In the remaining 20 cases that were performed with either or both plasma therapy or eculizumab administration, transplantation was successful in 16 patients. There were three deaths, and in one patient, liver transplantation was successful, but the renal transplant never gained function. Of this group of 20 patients, 16 had <em>CFH</em> variants (14 successful outcomes), 1 with <em>CFB</em> variant (successful), 1 with C3 variant (unsuccessful), and 2 with <em>CFH</em>/<em>CFHR1</em> hybrid variants (one successful).</p><p>The decision of combined liver-renal transplantation to definitively cure the disease is based on an evaluation that carefully weighs the risks and benefits for the individual patient. It should only be performed in pediatric centers with expertise in solid combined organ transplantation and with provision of preparative measures to control complement activation. The decision to perform combined liver-renal transplantation should be taken on a case-by-case basis, after discussion with the patient and families, taking into account the benefits and risks of each option and the cost of the long-term <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> treatment. In patients with high risk of recurrence and preserved renal function, isolated liver transplantation may be an option.</p><p class="headingAnchor" id="H2668893306"><span class="h1">OUTCOME</span></p><p class="headingAnchor" id="H1320701947"><span class="h2">Patient with complement antibodies</span><span class="headingEndMark"> — </span>Outcome of patients with CFH antibodies varies as demonstrated by the following case series:</p><p class="bulletIndent1"><span class="glyph">●</span>In one case series, outcome data at a mean follow-up of 39 months were available for 44 of the 45 patients [<a href="#rid21">21</a>]. Four patients died (unknown cause in two patients, one from pulmonary arterial hypertension, and one from cardiac disease), 25 patients had relapses, 17 developed chronic kidney disease (CKD) including 12 who went on to end-stage kidney disease (ESKD), and 11 patients had no sequelae.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study from the United Kingdom and Ireland, six patients progressed to ESKD (two who received only supportive care and four who also received plasma exchange), and the others regained kidney function, including six patients with sustained remission who were treated with <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> [<a href="#rid26">26</a>]. Five patients received kidney transplants without specific factor H autoantibody-targeted treatment, and recurrence occurred in one patient who also had a functionally significant CFI variant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A large case series of 138 patients from India reported mean follow-up at 14.5 months for patients who mostly were treated with early plasma exchange therapy and/or immunosuppressive therapy [<a href="#rid141">141</a>]. Plasma exchange was performed in 105 patients and 87 received immunosuppressive therapy, which included oral <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> with or without additional agents such as intravenous <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">cyclophosphamide</a> (n = 49) and <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">rituximab</a> (n = 18). The following outcomes were noted:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>58 patients had normal kidney function with hypertension and/or significant hematuria/proteinuria</p><p class="bulletIndent2"><span class="glyph">•</span>33 patients remained on dialysis</p><p class="bulletIndent2"><span class="glyph">•</span>20 deaths</p><p class="bulletIndent2"><span class="glyph">•</span>13 patients with normal kidney function and normal urinalysis</p><p class="bulletIndent2"><span class="glyph">•</span>10 patients with impaired kidney function, but not dialysis dependent</p><p class="bulletIndent2"><span class="glyph">•</span>3 patients underwent transplantation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 19 children who were treated initially with plasma exchanges and only steroids for immunosuppression, relapses occurred 14 patients [<a href="#rid29">29</a>]. All patients had their first relapse during the first six months after diagnosis. Although 13 of 19 children required initial kidney replacement therapy, only 5 (26 percent) remained on dialysis at one- and two-year follow-up. After five years, two of these five children received a kidney transplant, two remained on dialysis, and one patient started on <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> was able to discontinue dialysis. </p><p></p><p class="headingAnchor" id="H2565293347"><span class="h2">Patients with genetic variants</span><span class="headingEndMark"> — </span>The clinical course and outcome vary depending on the affected complement component [<a href="#rid34">34,50</a>]. Without treatment, patients with variants of the gene for CFH have a high likelihood of progressing to ESKD; though the risk is substantially reduced with <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> treatment (see <a class="local">'Complement blockade (eculizumab)'</a> above). By contrast, few patients harboring variants that affect CD46 progress to ESKD, although relapse is common [<a href="#rid50">50</a>]. (See <a class="local">'Genetic variants'</a> above.)</p><p class="headingAnchor" id="H3117151613"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117977.html" rel="external">"Society guideline links: Hemolytic uremic syndrome in children"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/117846.html" rel="external">"Society guideline links: Thrombotic microangiopathies (TTP, HUS, and related disorders)"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition </strong>‒ Hemolytic uremic syndrome (HUS) is defined by the concurrent characteristic triad of HUS: microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. The most common cause of HUS is due to Shiga toxin-producing <em>Escherichia coli</em> (STEC). Complement-mediated HUS accounts for most of the non-STEC-HUS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>‒ Complement-mediated HUS is a relatively rare disorder, with an estimated prevalence of seven per one million children in Europe. Most complement-mediated HUS cases are due to gene variants of complement factors, although acquired complement dysregulation due to antibodies to complement proteins occurs in 6 to 10 percent of patients with complement-mediated HUS. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> ‒ The complement proteins associated with complement-mediated HUS are components of the alternative complement pathway. They include complement factors H, I, and B (CFH, CFI, and CFB), C3, CD46 (previously known as membrane cofactor protein [MCP]), and thrombomodulin (THBD). (See <a class="local">'Genetic complement disorders'</a> above and <a class="local">'Genetic variants'</a> above and <a class="local">'Complement antibodies'</a> above.)</p><p></p><p class="bulletIndent1">The proposed pathogenesis of complement-mediated HUS is that a trigger (eg, infection) causes uninhibited continuous activation of the alternative complement pathway in a susceptible individual with either gene variants or antibodies to complement proteins. This results in renal endothelial damage leading to thrombotic microangiopathy. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> ‒ In addition to the clinical triad of HUS (microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury), patients with complement-mediated HUS typically will have a history of a triggering antecedent event (eg, upper respiratory infection or diarrheal illness). There is often a positive family history, and/or a history of a previous episode. Severe hypertension is a common clinical finding. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical course and outcome</strong> ‒ The clinical course and outcome vary depending on the affected complement component. (See <a class="local">'Clinical course and outcome'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with <em>CFH</em> variants generally have a poor prognosis with most patients progressing to end-stage kidney disease (ESKD) or death within the first year of presentation. (See <a class="local">'Factor H'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In contrast, patients with variants of <em>CD46</em> do not usually progress to ESKD, although relapse is common. (See <a class="local">'CD46'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with <em>CFI</em> variants have an intermediate course between those with <em>CFH</em> and <em>CD46</em> variants, with one-half of patients progressing to ESKD or death within two years of presentation. (See <a class="local">'Factor I'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> ‒ The diagnostic evaluation consists of laboratory studies that differentiate complement-mediated HUS from other conditions that have similar presentations. This includes testing for STEC, cultures of blood and other pertinent bodily fluids (eg, cerebral spinal fluid, urine, or sputum), complement studies, <em>ADAMTS13</em> activity, and occasionally kidney biopsy. (See <a class="local">'Evaluation'</a> above and  <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">"Overview of hemolytic uremic syndrome in children", section on 'Evaluation to identify underlying etiology'</a> and  <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>‒ The diagnosis of complement-mediated HUS is based upon the classical triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury, <strong>plus</strong> demonstration of complement dysregulation, either due to a genetic variant or antibodies to complement factors. Laboratories that offer complement genotyping for complement-mediated HUS can be found from the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2FGeneTests%2Flab%2Fdisease%2Fatypical+hus%3Fdb%3Dgenetests%26search_param%3Dcontains&amp;token=oNz6QKpDtHy%2BIr7LKk2pP66SxGN%2BcNNVbblZmB5n8QcHJnCJKoRRtKxco8XiH%2BkhSZWtjCCPEiuOKf6wyS%2BRqlOhOwso4i821huqgbD%2B2C7u%2Fe4Xj2F4JtkgTQx7Zj%2FPrwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=6084" target="_blank">National Center for Biotechnology Information website</a>. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> ‒ The differential diagnosis of complement-mediated HUS includes other forms of HUS (eg, STEC-HUS), thrombotic thrombocytopenic purpura (TTP), and inborn errors of vitamin B12. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> ‒ (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The initial management of complement-mediated HUS is supportive and similar to the approach used for STEC-HUS. (See <a class="local">'Supportive care'</a> above and  <a class="medical medical_review" href="/z/d/html/6097.html" rel="external">"Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children", section on 'Supportive therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients in with severe forms of complement-mediated HUS (eg, patients with <em>CFH</em> and <em>CFI</em> variants), we recommend <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). If eculizumab therapy is not available, plasma therapy is an alternative treatment option. (See <a class="local">'Complement blockade (eculizumab)'</a> above and <a class="local">'Plasma therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with HUS due to CFH antibodies, we suggest initial treatment with plasma exchange followed by immunosuppressive therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Patients with complement antibodies'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with HUS who progress to ESKD and undergo evaluation for kidney transplantation, complement genotyping should be performed if it was not already done. Complement genotyping will identify the presence and nature of an underlying gene, which informs the risk of recurrent disease in the allograft. (See <a class="local">'Kidney transplantation'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In our center, living-related donor transplantation is not performed <strong>unless</strong> donor genetic testing has been completed to ensure that the same variant is not present in the potential living donor. (See <a class="local">'Kidney transplantation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For kidney transplant recipients who are at risk for recurrent disease in the allograft, we suggest prophylactic administration of <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">eculizumab</a> rather than plasma therapy or no treatment (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). At-risk patients include those with with an identified variant in <em>CFH</em>, <em>CFI</em>, <em>C3</em>, or <em>CFB</em>, those with high titers of CFH antibodies, and those with a previous post-transplant episode of recurrent disease. If eculizumab is not available (eg, due to cost constraints), plasma therapy is an acceptable alternative. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Combined liver-renal transplantation provides a definitive cure for complement-mediated HUS with variants of <em>CFH</em>, <em>CFI</em>, <em>CFB</em>, and <em>C3</em>. However, this procedure carries a risk of death in the postoperative period. It should only be performed in pediatric centers with expertise in solid combined organ transplantation and after careful consideration of the risks and benefits for the individual patient. (See <a class="local">'Combined liver-renal transplantation'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16:1035.</a></li><li><a class="nounderline abstract_t">Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017; 91:539.</a></li><li><a class="nounderline abstract_t">Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet 2017; 390:681.</a></li><li><a class="nounderline abstract_t">Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clin Kidney J 2019; 12:333.</a></li><li><a class="nounderline abstract_t">Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2016; 31:15.</a></li><li><a class="nounderline abstract_t">Taylor CM, Machin S, Wigmore SJ, et al. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 2010; 148:37.</a></li><li><a class="nounderline abstract_t">Geerdink LM, Westra D, van Wijk JA, et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol 2012; 27:1283.</a></li><li><a class="nounderline abstract_t">Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5:1844.</a></li><li><a class="nounderline abstract_t">Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol 2011; 26:41.</a></li><li><a class="nounderline abstract_t">Kavanagh D, Richards A, Fremeaux-Bacchi V, et al. Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2007; 2:591.</a></li><li><a class="nounderline abstract_t">Hofer J, Janecke AR, Zimmerhackl LB, et al. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2013; 8:407.</a></li><li><a class="nounderline abstract_t">Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361:1676.</a></li><li><a class="nounderline abstract_t">Noris M, Remuzzi G. Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management? Nat Clin Pract Nephrol 2005; 1:2.</a></li><li><a class="nounderline abstract_t">Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013; 8:554.</a></li><li><a class="nounderline abstract_t">Bu F, Zhang Y, Wang K, et al. Genetic Analysis of 400 Patients Refines Understanding and Implicates a New Gene in Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol 2018; 29:2809.</a></li><li><a class="nounderline abstract_t">Esparza-Gordillo J, Jorge EG, Garrido CA, et al. Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol Immunol 2006; 43:1769.</a></li><li><a class="nounderline abstract_t">Ardissino G, Longhi S, Porcaro L, et al. Risk of Atypical HUS Among Family Members of Patients Carrying Complement Regulatory Gene Abnormality. Kidney Int Rep 2021; 6:1614.</a></li><li><a class="nounderline abstract_t">Fakhouri F, Frémeaux-Bacchi V. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol 2021; 17:543.</a></li><li><a class="nounderline abstract_t">Huerta A, Arjona E, Portoles J, et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int 2018; 93:450.</a></li><li><a class="nounderline abstract_t">de Jorge EG, Macor P, Paixão-Cavalcante D, et al. The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol 2011; 22:137.</a></li><li><a class="nounderline abstract_t">Dragon-Durey MA, Sethi SK, Bagga A, et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010; 21:2180.</a></li><li><a class="nounderline abstract_t">Józsi M, Strobel S, Dahse HM, et al. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 2007; 110:1516.</a></li><li><a class="nounderline abstract_t">Józsi M, Licht C, Strobel S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008; 111:1512.</a></li><li><a class="nounderline abstract_t">Abarrategui-Garrido C, Martínez-Barricarte R, López-Trascasa M, et al. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 2009; 114:4261.</a></li><li><a class="nounderline abstract_t">Moore I, Strain L, Pappworth I, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010; 115:379.</a></li><li><a class="nounderline abstract_t">Brocklebank V, Johnson S, Sheerin TP, et al. Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland. Kidney Int 2017; 92:1261.</a></li><li><a class="nounderline abstract_t">Iorember F, Nayak A. Deficiency of CFHR plasma proteins and autoantibody positive hemolytic uremic syndrome: treatment rationale, outcomes, and monitoring. Pediatr Nephrol 2021; 36:1365.</a></li><li><a class="nounderline abstract_t">Watson R, Lindner S, Bordereau P, et al. Standardisation of the factor H autoantibody assay. Immunobiology 2014; 219:9.</a></li><li><a class="nounderline abstract_t">Hofer J, Riedl Khursigara M, Perl M, et al. Early relapse rate determines further relapse risk: results of a 5-year follow-up study on pediatric CFH-Ab HUS. Pediatr Nephrol 2021; 36:917.</a></li><li><a class="nounderline abstract_t">Dragon-Durey MA, Blanc C, Marliot F, et al. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 2009; 46:447.</a></li><li><a class="nounderline abstract_t">Le Clech A, Simon-Tillaux N, Provôt F, et al. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors. Kidney Int 2019; 95:1443.</a></li><li><a class="nounderline abstract_t">Rodríguez de Córdoba S. aHUS: a disorder with many risk factors. Blood 2010; 115:158.</a></li><li><a class="nounderline abstract_t">Cugno M, Berra S, Depetri F, et al. IgM Autoantibodies to Complement Factor H in Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol 2021; 32:1227.</a></li><li><a class="nounderline abstract_t">Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108:1267.</a></li><li><a class="nounderline abstract_t">Martín Merinero H, Zhang Y, Arjona E, et al. Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification. Blood 2021; 138:2185.</a></li><li><a class="nounderline abstract_t">Heinen S, Józsi M, Hartmann A, et al. Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells. J Am Soc Nephrol 2007; 18:506.</a></li><li><a class="nounderline abstract_t">Jokiranta TS, Jaakola VP, Lehtinen MJ, et al. Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO J 2006; 25:1784.</a></li><li><a class="nounderline abstract_t">Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17:405.</a></li><li><a class="nounderline abstract_t">Warwicker P, Goodship TH, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998; 53:836.</a></li><li><a class="nounderline abstract_t">Caprioli J, Bettinaglio P, Zipfel PF, et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 2001; 12:297.</a></li><li><a class="nounderline abstract_t">Warwicker P, Donne RL, Goodship JA, et al. Familial relapsing haemolytic uraemic syndrome and complement factor H deficiency. Nephrol Dial Transplant 1999; 14:1229.</a></li><li><a class="nounderline abstract_t">Rougier N, Kazatchkine MD, Rougier JP, et al. Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol 1998; 9:2318.</a></li><li><a class="nounderline abstract_t">Noris M, Remuzzi G. Are HUS and TTP genetically determined? Kidney Int 1998; 53:1085.</a></li><li><a class="nounderline abstract_t">Warwicker P, Goodship JA, Goodship TH. Factor H--US? Nephrol Dial Transplant 1998; 13:1921.</a></li><li><a class="nounderline abstract_t">Dragon-Durey MA, Frémeaux-Bacchi V, Loirat C, et al. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 2004; 15:787.</a></li><li><a class="nounderline abstract_t">Ohali M, Shalev H, Schlesinger M, et al. Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H. Pediatr Nephrol 1998; 12:619.</a></li><li><a class="nounderline abstract_t">Landau D, Shalev H, Levy-Finer G, et al. Familial hemolytic uremic syndrome associated with complement factor H deficiency. J Pediatr 2001; 138:412.</a></li><li><a class="nounderline abstract_t">Vaziri-Sani F, Holmberg L, Sjöholm AG, et al. Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome. Kidney Int 2006; 69:981.</a></li><li><a class="nounderline abstract_t">Ståhl AL, Vaziri-Sani F, Heinen S, et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 2008; 111:5307.</a></li><li><a class="nounderline abstract_t">Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007; 18:2392.</a></li><li><a class="nounderline abstract_t">Post TW, Liszewski MK, Adams EM, et al. Membrane cofactor protein of the complement system: alternative splicing of serine/threonine/proline-rich exons and cytoplasmic tails produces multiple isoforms that correlate with protein phenotype. J Exp Med 1991; 174:93.</a></li><li><a class="nounderline abstract_t">Noris M, Brioschi S, Caprioli J, et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003; 362:1542.</a></li><li><a class="nounderline abstract_t">Richards A, Kemp EJ, Liszewski MK, et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2003; 100:12966.</a></li><li><a class="nounderline abstract_t">Fremeaux-Bacchi V, Moulton EA, Kavanagh D, et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2006; 17:2017.</a></li><li><a class="nounderline abstract_t">Fang CJ, Fremeaux-Bacchi V, Liszewski MK, et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 2008; 111:624.</a></li><li><a class="nounderline abstract_t">Klämbt V, Gimpel C, Bald M, et al. Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis. Pediatr Nephrol 2021; 36:463.</a></li><li><a class="nounderline abstract_t">Kavanagh D, Kemp EJ, Mayland E, et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16:2150.</a></li><li><a class="nounderline abstract_t">Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004; 41:e84.</a></li><li><a class="nounderline abstract_t">Bienaime F, Dragon-Durey MA, Regnier CH, et al. Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int 2010; 77:339.</a></li><li><a class="nounderline abstract_t">Schramm EC, Roumenina LT, Rybkine T, et al. Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood 2015; 125:2359.</a></li><li><a class="nounderline abstract_t">Frémeaux-Bacchi V, Miller EC, Liszewski MK, et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008; 112:4948.</a></li><li><a class="nounderline abstract_t">Roumenina LT, Frimat M, Miller EC, et al. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood 2012; 119:4182.</a></li><li><a class="nounderline abstract_t">Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2007; 104:240.</a></li><li><a class="nounderline abstract_t">Roumenina LT, Jablonski M, Hue C, et al. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 2009; 114:2837.</a></li><li><a class="nounderline abstract_t">Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361:345.</a></li><li><a class="nounderline abstract_t">Fidan K, Göknar N, Gülhan B, et al. Extra-Renal manifestations of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2018; 33:1395.</a></li><li><a class="nounderline abstract_t">Formeck C, Swiatecka-Urban A. Extra-renal manifestations of atypical hemolytic uremic syndrome. Pediatr Nephrol 2019; 34:1337.</a></li><li><a class="nounderline abstract_t">Neumann HP, Salzmann M, Bohnert-Iwan B, et al. Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet 2003; 40:676.</a></li><li><a class="nounderline abstract_t">Sridharan M, Go RS, Abraham RS, et al. Diagnostic Utility of Complement Serology for Atypical Hemolytic Uremic Syndrome. Mayo Clin Proc 2018; 93:1351.</a></li><li><a class="nounderline abstract_t">Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011; 6:60.</a></li><li class="breakAll">Habib R. Pathology of the hemolytic uremic syndrome. In: Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura, Kaplan B, Trompeter R, Moake J (Eds), Marcel Dekker, New York 1992. p.315.</li><li><a class="nounderline abstract_t">Arjona E, Huerta A, Goicoechea de Jorge E, Rodríguez de Córdoba S. Familial risk of developing atypical hemolytic-uremic syndrome. Blood 2020; 136:1558.</a></li><li><a class="nounderline abstract_t">Feng S, Eyler SJ, Zhang Y, et al. Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. Blood 2013; 122:1487.</a></li><li><a class="nounderline abstract_t">Durey MA, Sinha A, Togarsimalemath SK, Bagga A. Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol 2016; 12:563.</a></li><li><a class="nounderline abstract_t">Boyer O, Balzamo E, Charbit M, et al. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies. Am J Kidney Dis 2010; 55:923.</a></li><li><a class="nounderline abstract_t">Sana G, Dragon-Durey MA, Charbit M, et al. Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol 2014; 29:75.</a></li><li><a class="nounderline abstract_t">Kwon T, Dragon-Durey MA, Macher MA, et al. Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 2008; 23:2088.</a></li><li><a class="nounderline abstract_t">Noone D, Waters A, Pluthero FG, et al. Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol 2014; 29:841.</a></li><li><a class="nounderline abstract_t">Diamante Chiodini B, Davin JC, Corazza F, et al. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome. Pediatrics 2014; 133:e1764.</a></li><li><a class="nounderline abstract_t">Cofiell R, Kukreja A, Bedard K, et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 2015; 125:3253.</a></li><li><a class="nounderline abstract_t">Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 2009; 373:759.</a></li><li><a class="nounderline abstract_t">Peffault de Latour R, Schrezenmeier H, Bacigalupo A, et al. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica 2012; 97:1666.</a></li><li><a class="nounderline abstract_t">Bagga A, Khandelwal P, Mishra K, et al. Hemolytic uremic syndrome in a developing country: Consensus guidelines. Pediatr Nephrol 2019; 34:1465.</a></li><li class="breakAll">US Food and Drug Administration. Dosing of Eculizumab in pediatric atypical hemolytic uremic syndrome. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125166s172lbl.pdf (Accessed on October 10, 2011).</li><li><a class="nounderline abstract_t">Noris M, Galbusera M, Gastoldi S, et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 2014; 124:1715.</a></li><li><a class="nounderline abstract_t">Cugno M, Gualtierotti R, Possenti I, et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 2014; 12:1440.</a></li><li><a class="nounderline abstract_t">Ardissino G, Tel F, Sgarbanti M, et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update. Pediatr Nephrol 2018; 33:457.</a></li><li><a class="nounderline abstract_t">McNamara LA, Topaz N, Wang X, et al. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. MMWR Morb Mortal Wkly Rep 2017; 66:734.</a></li><li><a class="nounderline abstract_t">Licht C, Greenbaum LA, Muus P, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 2015; 87:1061.</a></li><li><a class="nounderline abstract_t">Martinón-Torres F, Bernatowska E, Shcherbina A, et al. Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic Function. Pediatrics 2018; 142.</a></li><li class="breakAll">Health Canada. Summary Safety Review - SOLIRIS (eculizumab) and BEXSERO (Multicomponent Meningococcal B Vaccine [recombinant, adsorbed]) - Assessing the Potential Risk of Hemolysis and Low Hemoglobin in Patients Treated with Soliris and Vaccinated with Bexsero. Available at: www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/soliris-bexsero-eng.php (Accessed on September 23, 2016).</li><li><a class="nounderline abstract_t">Olson SR, Lu E, Sulpizio E, et al. When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies. Am J Nephrol 2018; 48:96.</a></li><li><a class="nounderline abstract_t">Ardissino G, Testa S, Possenti I, et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis 2014; 64:633.</a></li><li><a class="nounderline abstract_t">Fakhouri F, Fila M, Provôt F, et al. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. Clin J Am Soc Nephrol 2017; 12:50.</a></li><li><a class="nounderline abstract_t">Merrill SA, Brittingham ZD, Yuan X, et al. Eculizumab cessation in atypical hemolytic uremic syndrome. Blood 2017; 130:368.</a></li><li><a class="nounderline abstract_t">Wijnsma KL, Duineveld C, Volokhina EB, et al. Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. Nephrol Dial Transplant 2018; 33:635.</a></li><li><a class="nounderline abstract_t">Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol 2019; 34:2261.</a></li><li><a class="nounderline abstract_t">Fakhouri F, Fila M, Hummel A, et al. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood 2021; 137:2438.</a></li><li><a class="nounderline abstract_t">Ariceta G. Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way. Pediatr Nephrol 2019; 34:943.</a></li><li><a class="nounderline abstract_t">Brodsky RA. Eculizumab and aHUS: to stop or not. Blood 2021; 137:2419.</a></li><li><a class="nounderline abstract_t">Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360:544.</a></li><li><a class="nounderline abstract_t">Nürnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360:542.</a></li><li><a class="nounderline abstract_t">Zimmerhackl LB, Hofer J, Cortina G, et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010; 362:1746.</a></li><li><a class="nounderline abstract_t">Lapeyraque AL, Frémeaux-Bacchi V, Robitaille P. Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol 2011; 26:621.</a></li><li><a class="nounderline abstract_t">Prescott HC, Wu HM, Cataland SR, Baiocchi RA. Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome. Am J Hematol 2010; 85:976.</a></li><li><a class="nounderline abstract_t">Al-Akash SI, Almond PS, Savell VH Jr, et al. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol 2011; 26:613.</a></li><li><a class="nounderline abstract_t">Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368:2169.</a></li><li><a class="nounderline abstract_t">Christmann M, Hansen M, Bergmann C, et al. Eculizumab as first-line therapy for atypical hemolytic uremic syndrome. Pediatrics 2014; 133:e1759.</a></li><li><a class="nounderline abstract_t">Greenbaum LA, Fila M, Ardissino G, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 2016; 89:701.</a></li><li><a class="nounderline abstract_t">Rathbone J, Kaltenthaler E, Richards A, et al. A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open 2013; 3:e003573.</a></li><li><a class="nounderline abstract_t">Muff-Luett M, Sanderson KR, Engen RM, et al. Eculizumab exposure in children and young adults: indications, practice patterns, and outcomes-a Pediatric Nephrology Research Consortium study. Pediatr Nephrol 2021; 36:2349.</a></li><li class="breakAll">US Food and Drug Administration. FDA approval for eculizumab in the treatment of atypical hemolytic uremic syndrome. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm272990.htm (Accessed on October 10, 2011).</li><li><a class="nounderline abstract_t">Sheerin NS, Kavanagh D, Goodship TH, Johnson S. A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience. QJM 2016; 109:27.</a></li><li><a class="nounderline abstract_t">Fakhouri F, Hourmant M, Campistol JM, et al. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. Am J Kidney Dis 2016; 68:84.</a></li><li><a class="nounderline abstract_t">Rondeau E, Scully M, Ariceta G, et al. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int 2020; 97:1287.</a></li><li><a class="nounderline abstract_t">Tanaka K, Adams B, Aris AM, et al. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Pediatr Nephrol 2021; 36:889.</a></li><li><a class="nounderline abstract_t">Ariceta G, Dixon BP, Kim SH, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int 2021; 100:225.</a></li><li><a class="nounderline abstract_t">Ehren R, Habbig S. Real-world data of six patients with atypical hemolytic uremic syndrome switched to ravulizumab. Pediatr Nephrol 2021; 36:3281.</a></li><li><a class="nounderline abstract_t">Davin JC, Strain L, Goodship TH. Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr Nephrol 2008; 23:1517.</a></li><li><a class="nounderline abstract_t">Lapeyraque AL, Wagner E, Phan V, et al. Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations. Pediatr Nephrol 2008; 23:1363.</a></li><li><a class="nounderline abstract_t">Licht C, Weyersberg A, Heinen S, et al. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis 2005; 45:415.</a></li><li><a class="nounderline abstract_t">Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost 2010; 36:673.</a></li><li><a class="nounderline abstract_t">Nathanson S, Ulinski T, Frémeaux-Bacchi V, Deschênes G. Secondary failure of plasma therapy in factor H deficiency. Pediatr Nephrol 2006; 21:1769.</a></li><li class="breakAll">Noris M, Bresin E, Mele C et al. Atypical Hemoltyic-Uremic Syndrome. GeneReviews. http://www.ncbi.nlm.nih.gov/books/NBK1367/ (Accessed on April 15, 2013).</li><li><a class="nounderline abstract_t">Loirat C, Niaudet P. The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol 2003; 18:1095.</a></li><li><a class="nounderline abstract_t">Zuber J, Le Quintrec M, Sberro-Soussan R, et al. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2011; 7:23.</a></li><li><a class="nounderline abstract_t">Zuber J, Le Quintrec M, Krid S, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012; 12:3337.</a></li><li><a class="nounderline abstract_t">Niaudet P. Living donor kidney transplantation in patients with hereditary nephropathies. Nat Rev Nephrol 2010; 6:736.</a></li><li><a class="nounderline abstract_t">Krid S, Roumenina LT, Beury D, et al. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant 2012; 12:1938.</a></li><li><a class="nounderline abstract_t">Nester C, Stewart Z, Myers D, et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2011; 6:1488.</a></li><li><a class="nounderline abstract_t">Weitz M, Amon O, Bassler D, et al. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 2011; 26:1325.</a></li><li><a class="nounderline abstract_t">Waters AM, Pappworth I, Marchbank K, et al. Successful renal transplantation in factor H autoantibody associated HUS with CFHR1 and 3 deficiency and CFH variant G2850T. Am J Transplant 2010; 10:168.</a></li><li><a class="nounderline abstract_t">Duval A, Olagne J, Cognard N, et al. Pregnancy in a Kidney Transplant Woman Under Treatment With Eculizumab for Atypical Hemolytic Uremic Syndrome: Is It Safe? Kidney Int Rep 2019; 4:733.</a></li><li><a class="nounderline abstract_t">Saland JM, Ruggenenti P, Remuzzi G, Consensus Study Group. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 2009; 20:940.</a></li><li><a class="nounderline abstract_t">Duineveld C, Verhave JC, Berger SP, et al. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series. Am J Kidney Dis 2017; 70:770.</a></li><li><a class="nounderline abstract_t">Noris M, Ruggenenti P, Remuzzi G. Kidney Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Therapeutic Dilemma (or Not)? Am J Kidney Dis 2017; 70:754.</a></li><li><a class="nounderline abstract_t">Chatelet V, Frémeaux-Bacchi V, Lobbedez T, et al. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009; 9:2644.</a></li><li><a class="nounderline abstract_t">Davin JC, Gracchi V, Bouts A, et al. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis 2010; 55:708.</a></li><li><a class="nounderline abstract_t">Larrea CF, Cofan F, Oppenheimer F, et al. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 2010; 89:903.</a></li><li><a class="nounderline abstract_t">Saland J. Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab? Pediatr Nephrol 2014; 29:329.</a></li><li><a class="nounderline abstract_t">Sinha A, Gulati A, Saini S, et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 2014; 85:1151.</a></li></ol></div><div id="topicVersionRevision">Topic 6084 Version 94.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728781" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27989322" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28242109" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Haemolytic uraemic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31198225" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25859752" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : An international consensus approach to the management of atypical hemolytic uremic syndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19821824" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22410797" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20595690" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20556434" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : aHUS caused by complement dysregulation: new therapies on the horizon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699467" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23243267" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19846853" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Atypical hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16932353" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23307876" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30377230" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Genetic Analysis of 400 Patients Refines Understanding and Implicates a New Gene in Atypical Hemolytic Uremic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16386793" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34169201" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Risk of Atypical HUS Among Family Members of Patients Carrying Complement Regulatory Gene Abnormality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33953366" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28911789" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21148255" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The development of atypical hemolytic uremic syndrome depends on complement C5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21051740" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17495132" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18006700" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19745068" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19861685" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28750931" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32529325" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Deficiency of CFHR plasma proteins and autoantibody positive hemolytic uremic syndrome: treatment rationale, outcomes, and monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23891327" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Standardisation of the factor H autoantibody assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33025207" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Early relapse rate determines further relapse risk: results of a 5-year follow-up study on pediatric CFH-Ab HUS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19435718" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30982675" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20075170" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : aHUS: a disorder with many risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33712527" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : IgM Autoantibodies to Complement Factor H in Atypical Hemolytic Uremic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16621965" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34189567" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17229916" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16601698" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25741868" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9551389" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Genetic studies into inherited and sporadic hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11158219" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10344366" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Familial relapsing haemolytic uraemic syndrome and complement factor H deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9848786" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Human complement factor H deficiency associated with hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9551421" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Are HUS and TTP genetically determined?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9719138" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Factor H--US?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14978182" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9811382" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11241053" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Familial hemolytic uremic syndrome associated with complement factor H deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16528247" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18268093" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17599974" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1711570" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Membrane cofactor protein of the complement system: alternative splicing of serine/threonine/proline-rich exons and cytoplasmic tails produces multiple isoforms that correlate with protein phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14615110" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Familial haemolytic uraemic syndrome and an MCP mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14566051" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16762990" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17914026" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32715379" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15917334" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15173250" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20016463" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25608561" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18796626" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22246034" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17182750" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19584399" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19625716" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Thrombomodulin mutations in atypical hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29610995" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Extra-Renal manifestations of atypical hemolytic uremic syndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30109445" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Extra-renal manifestations of atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12960213" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30286829" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Diagnostic Utility of Complement Serology for Atypical Hemolytic Uremic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21902819" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21902819" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32488248" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Familial risk of developing atypical hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23847193" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27452363" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Anti-complement-factor H-associated glomerulopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20202729" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23868108" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18326881" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24249282" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Successful treatment of DEAP-HUS with eculizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24843055" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25833956" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19144399" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Eculizumab for paroxysmal nocturnal haemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22689687" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30989342" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Hemolytic uremic syndrome in a developing country: Consensus guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30989342" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Hemolytic uremic syndrome in a developing country: Consensus guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25037630" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24853860" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29046944" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28704351" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25651368" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30068713" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30068713" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30110670" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24656451" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27799617" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28461395" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Eculizumab cessation in atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29106598" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30402748" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33270832" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30693384" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33956069" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Eculizumab and aHUS: to stop or not.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19179329" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Eculizumab for congenital atypical hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19179328" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Eculizumab for atypical hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20445192" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21161283" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20941783" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21125405" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23738544" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24843059" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Eculizumab as first-line therapy for atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26880462" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24189082" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33693990" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Eculizumab exposure in children and young adults: indications, practice patterns, and outcomes-a Pediatric Nephrology Research Consortium study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33693990" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Eculizumab exposure in children and young adults: indications, practice patterns, and outcomes-a Pediatric Nephrology Research Consortium study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25899302" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27012908" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32299680" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33048203" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33307104" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34274988" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Real-world data of six patients with atypical hemolytic uremic syndrome switched to ravulizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18483746" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18425537" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15685522" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20865645" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Plasmatherapy in atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16909242" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Secondary failure of plasma therapy in factor H deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16909242" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Secondary failure of plasma therapy in factor H deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13680331" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21102542" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : New insights into postrenal transplant hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22958221" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20877305" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Living donor kidney transplantation in patients with hereditary nephropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22494769" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21617085" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21556717" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19951285" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Successful renal transplantation in factor H autoantibody associated HUS with CFHR1 and 3 deficiency and CFH variant G2850T.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31080930" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Pregnancy in a Kidney Transplant Woman Under Treatment With Eculizumab for Atypical Hemolytic Uremic Syndrome: Is It Safe?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19092117" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Liver-kidney transplantation to cure atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28821363" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29169515" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Kidney Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Therapeutic Dilemma (or Not)?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19775316" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19854549" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20386298" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24362724" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24088957" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
